{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:56Z","timestamp":1792114136224,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"German Centre for Infection Research","doi-asserted-by":"publisher","award":["FKZ80095CLANF"],"award-info":[{"award-number":["FKZ80095CLANF"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Centre for Infection Research","doi-asserted-by":"publisher","award":["FKZ8009701702"],"award-info":[{"award-number":["FKZ8009701702"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Centre for Infection Research","doi-asserted-by":"publisher","award":["FKZ8009801908"],"award-info":[{"award-number":["FKZ8009801908"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["AD171\/3-1"],"award-info":[{"award-number":["AD171\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.xcrm.2022.100685","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T11:08:56Z","timestamp":1658228936000},"page":"100685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1175-7354","authenticated-orcid":false,"given":"Leonie M.","family":"Weskamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs P.","family":"Raadsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Z.","family":"Mykytyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0140-2808","authenticated-orcid":false,"given":"Till","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9160-4157","authenticated-orcid":false,"given":"Michael","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swantje","family":"Gundlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hesterkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Kr\u00e4hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My Linh","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"P\u00f6tsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schmiedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asisa","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine E.","family":"Zinser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Haagmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-9195","authenticated-orcid":false,"given":"Christine","family":"Dahlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marylyn M.","family":"Addo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2022.100685_bib1","series-title":"MERS Situation Update","year":"2021"},{"key":"10.1016\/j.xcrm.2022.100685_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nm.4131","article-title":"A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation","volume":"22","author":"Modjarrad","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100685_bib3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100685_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/zph.12171","article-title":"Human-dromedary camel interactions and the risk of acquiring zoonotic Middle East respiratory syndrome coronavirus infection","volume":"63","author":"Gossner","year":"2016","journal-title":"Zoonoses Public Health"},{"key":"10.1016\/j.xcrm.2022.100685_bib5","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S1473-3099(18)30127-0","article-title":"Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission","volume":"18","author":"Hui","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100685_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1473-3099(13)70304-9","article-title":"Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility","volume":"14","author":"Cauchemez","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100685_bib7","doi-asserted-by":"crossref","first-page":"9081","DOI":"10.1073\/pnas.1519235113","article-title":"Unraveling the drivers of MERS-CoV transmission","volume":"113","author":"Cauchemez","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2022.100685_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/0264-410X(96)00062-X","article-title":"Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination","volume":"14","author":"West","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2022.100685_bib10","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.vaccine.2005.08.058","article-title":"Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination","volume":"24","author":"Bauer","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2022.100685_bib11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","article-title":"Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus","volume":"10","author":"Yong","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.xcrm.2022.100685_bib12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5483\/BMBRep.2019.52.6.185","article-title":"Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex","volume":"52","author":"Park","year":"2019","journal-title":"BMB Rep."},{"key":"10.1016\/j.xcrm.2022.100685_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.xcrm.2022.100685_bib14","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100685_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14760584.2014.912134","article-title":"Current advancements and potential strategies in the development of MERS-CoV vaccines","volume":"13","author":"Zhang","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.xcrm.2022.100685_bib16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","volume":"20","author":"Koch","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100685_bib17","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100685_bib18","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100685_bib19","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2666-5247(21)00193-2","article-title":"Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial","volume":"3","author":"Bosaeed","year":"2022","journal-title":"Lancet Microbe."},{"key":"10.1016\/j.xcrm.2022.100685_bib20","doi-asserted-by":"crossref","first-page":"11950","DOI":"10.1128\/JVI.01672-13","article-title":"Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies","volume":"87","author":"Song","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100685_bib21","article-title":"Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome","author":"Fathi","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.xcrm.2022.100685_bib22","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and opportunities for consistent\u00a0classification of human B cell and plasma cell populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2022.100685_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2022.100685_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-020-0175-8","article-title":"Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations","volume":"5","author":"Palgen","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.xcrm.2022.100685_bib25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","article-title":"From vaccines to memory and back","volume":"33","author":"Sallusto","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2022.100685_bib26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100685_bib27","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/S0140-6736(21)00976-4","article-title":"ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - authors' reply","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100685_bib28","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2352-3018(19)30406-0","article-title":"Late boosting of the RV144 regimen with AIDSVAX B\/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial","volume":"7","author":"Pitisuttithum","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.xcrm.2022.100685_bib29","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100685_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/infdis\/jiy214","article-title":"Induction of cross-clade antibody and T-cell responses by a modified vaccinia virus ankara-based influenza A(H5N1) vaccine in a randomized phase 1\/2a clinical trial","volume":"218","author":"de Vries","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100685_bib31","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100685_bib32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41467-021-21968-w","article-title":"A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100685_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01991-20","article-title":"S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit","volume":"11","author":"Nguyen-Contant","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.xcrm.2022.100685_bib34","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","article-title":"Compromised humoral functional evolution tracks with SARS-CoV-2 mortality","volume":"183","author":"Zohar","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100685_bib35","doi-asserted-by":"crossref","first-page":"140925","DOI":"10.1172\/jci.insight.140925","article-title":"IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees","volume":"5","author":"Fischinger","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2022.100685_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/imm.12861","article-title":"Prospects from systems serology research","volume":"153","author":"Arnold","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.xcrm.2022.100685_bib37","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1002\/cti2.1258","article-title":"Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features","volume":"10","author":"Rowntree","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.xcrm.2022.100685_bib38","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41467-021-22236-7","article-title":"Systems serology detects functionally distinct coronavirus antibody features in children and elderly","volume":"12","author":"Selva","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100685_bib39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fimmu.2019.00440","article-title":"Extra-neutralizing FcR-mediated antibody functions for a universal influenza vaccine","volume":"10","author":"Boudreau","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2022.100685_bib40","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41591-021-01372-z","article-title":"Author Correction: phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100685_bib41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.it.2019.01.005","article-title":"Role of IgG3 in infectious diseases","volume":"40","author":"Damelang","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2022.100685_bib42","doi-asserted-by":"crossref","first-page":"228ra38","DOI":"10.1126\/scitranslmed.3007736","article-title":"Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines","volume":"6","author":"Chung","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2022.100685_bib43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100685_bib44","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2022.100685_bib45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T\u00a0cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2022.100685_bib46","doi-asserted-by":"crossref","first-page":"e550","DOI":"10.1093\/cid\/ciaa1345","article-title":"Sustained responses of neutralizing antibodies against Middle East respiratory syndrome coronavirus (MERS-CoV) in recovered patients and their therapeutic applicability","volume":"73","author":"Kim","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100685_bib47","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2022.100685_bib48","doi-asserted-by":"crossref","first-page":"e15227","DOI":"10.15252\/emmm.202115227","article-title":"Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection","volume":"14","author":"Tay","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2022.100685_bib49","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cmi.2021.06.009","article-title":"Longevity of seropositivity and neutralizing antibodies in recovered MERS patients: a 5-year follow-up study","volume":"28","author":"Cheon","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.xcrm.2022.100685_bib51","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3201\/eid2206.160010","article-title":"Antibody Response and Disease Severity in Healthcare Worker MERS Survivors","volume":"22","author":"Alshukairi","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.xcrm.2022.100685_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jim.2012.09.007","article-title":"High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples","volume":"386","author":"Brown","year":"2012","journal-title":"J.\u00a0Immunol. Methods"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912200221X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912200221X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:52:39Z","timestamp":1762987959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266637912200221X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S266637912200221X"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100685","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100685"}}